Cardiovascular disease is one of the leading causes of death in Canada and often referred to as the “silent killer” because of its lack of symptoms during disease progression. Although there are many identified risk factors for cardiovascular disease, abnormal blood clotting can be problematic in certain individuals. Therefore, this specific population can benefit from any intervention that can aid in breaking up pre-formed blood clots or preventing new clots.
Nattokinase is an enzyme derived from fermented soybean that contains powerful health potential. Nattokinase has dozens of human clinical studies to demonstrate its safety and efficacy in supporting the cardiovascular system, including healthy lipid balance, fibrinolytic activity and lowered inflammatory markers. It has been extensively studied for its ability to thin the blood, and break up blood clots.
Nattokinase achieves these cardiovascular benefits through multiple mechanisms. For example, increased fibrinolysis activity is well-documented and the primary reason that nattokinase is able to improve blood flow. However, it has also been shown to inhibit platelet aggregation, reduce C-reactive protein, decrease renin and reduce LDL-cholesterol. Numerous safety studies in both animals and humans have also confirmed that nattokinase is well tolerated under a wide variety of circumstances.
Cyto-Matrix‘s Nattokinase offers 100mg per vegetable capsule of the clinically studied NSK-SD® Nattokinase to effectively thin the blood, and break up blood clots. Each 100mg vegetable capsule offers the minimum equivalent of 2000 F.U. (fibrinolytic units) for optimal cardiovascular support. 60 vegetable capsules per bottle.
